Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Toxicity Costs Among Patients With Melanoma Receiving Ipilimumab and Nivolumab
07/14/2021
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of...
07/14/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-World PFS Among Patients With Ovarian Cancer Receiving First-Line Maintenance Therapy vs Active Surveillance
07/14/2021
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with...
07/14/2021
Journal of Clinical Pathways
Conference Coverage
US Budget Impact of Rituximab-abbs vs Subcutaneous Rituximab for CLL and NHL
07/14/2021
A budget impact model estimated that intravenous rituximab-abbs may yield significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
A budget impact model estimated that intravenous rituximab-abbs may yield significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
A budget impact model estimated...
07/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-world Safety and Efficacy of Bendamustine Plus Rituximab for Indolent NHL or MCL
07/13/2021
Study results show bendamustine plus rituximab is feasible for patients with NHL or MCL in the real-world setting.
Study results show bendamustine plus rituximab is feasible for patients with NHL or MCL in the real-world setting.
Study results show bendamustine...
07/13/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-World Daratumumab Response Across Lines of Therapy for Patients With MM
07/12/2021
A recent real-world study suggests that daratumumab-based regimens are an effective treatment option for MM across all lines of therapy, presenting the strongest response in the first-line setting.
A recent real-world study suggests that daratumumab-based regimens are an effective treatment option for MM across all lines of therapy, presenting the strongest response in the first-line setting.
A recent real-world study...
07/12/2021
Journal of Clinical Pathways
Conference Coverage
Budget Impact Analysis of Body Surface Area vs Flat-Fixed Rituximab Dosing for NHL and CLL
07/08/2021
Study findings suggest there may be economic benefit in replacing a proportion of flat-fixed rituximab/hyaluronidase human subcutaneous injection use with body surface area-based rituximab-abbs for patients with NHL and CLL from a US payer...
Study findings suggest there may be economic benefit in replacing a proportion of flat-fixed rituximab/hyaluronidase human subcutaneous injection use with body surface area-based rituximab-abbs for patients with NHL and CLL from a US payer...
Study findings suggest there may...
07/08/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiotherapy for Gastric Cancer
07/07/2021
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing...
07/07/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-world Treatment Patterns and Outcomes Among Patients With MCL in the United States
07/02/2021
Findings from a real-world study show bendamustine plus rituximab was the most commonly used first-line treatment for MCL in the United States and that receipt of stem cell transplant was not common.
Findings from a real-world study show bendamustine plus rituximab was the most commonly used first-line treatment for MCL in the United States and that receipt of stem cell transplant was not common.
Findings from a real-world study...
07/02/2021
Journal of Clinical Pathways
Conference Coverage
Health Care Burden of Patients Hospitalized for Testicular Carcinoma
07/02/2021
Increasing costs of stay for patients hospitalized with testicular carcinoma are out of proportion with increases in length of stay, leading to significant financial toxicity for these patients.
Increasing costs of stay for patients hospitalized with testicular carcinoma are out of proportion with increases in length of stay, leading to significant financial toxicity for these patients.
Increasing costs of stay for...
07/02/2021
Journal of Clinical Pathways
Conference Coverage
Real-world PSA Progression After Enzalutamide or Abiraterone for Metastatic CRPC
06/24/2021
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at...
06/24/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use